Aerosolized Recombinant Human DNase I for the Treatment of Cystic Fibrosis

This publication has 12 references indexed in Scilit:

• Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis
  New England Journal of Medicine, 1994
• Cystic Fibrosis in the Year 2000
  Seminars in Respiratory and Critical Care Medicine, 1994
• Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.
  American Journal of Respiratory and Critical Care Medicine, 1994
• Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.
  American Journal of Respiratory and Critical Care Medicine, 1994
• Consensus conference: Practical applications of pulmozyme® september 22, 1993
  Pediatric Pulmonology, 1994
• Efficacy and Safety of Short-term Administration of Aerosolized Recombinant Human Deoxyribonuclease in Patients with Cystic Fibrosis
  American Review of Respiratory Disease, 1993
• Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis
  The Lancet, 1993
• The changing epidemiology of cystic fibrosis
  The Journal of Pediatrics, 1993
• Recombinant Human DNase Inhalation in Normal Subjects and Patients With Cystic Fibrosis
  JAMA, 1992
• A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis
  New England Journal of Medicine, 1992